The Outside-In Journey of Tissue Transglutaminase in Cancer

Livia Elena Sima1, Daniela Matei2,3,4, Salvatore Condello5,6

  • 1Department of Molecular Cell Biology, Institute of Biochemistry of the Romanian Academy, 060031 Bucharest, Romania.

Cells
|June 10, 2022
PubMed

Insights

Tissue transglutaminase (TG2) regulates cancer progression by linking extracellular signals to oncogenic pathways. Understanding TG2

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Tissue transglutaminase (TG2) is a Ca2+-dependent enzyme involved in protein crosslinking and GTP hydrolysis.
  • TG2's conformation and activity are modulated by Ca2+ and GTP levels, influencing its cellular and extracellular functions.
  • Aberrant TG2 expression correlates with cancer progression, metastasis, chemoresistance, stemness, and poor clinical outcomes.

Purpose of the Study:

  • To review the current understanding of TG2's involvement in cancer.
  • To elucidate TG2's mechanisms in translating extracellular cues into oncogenic programs.
  • To highlight TG2 as a potential therapeutic target in cancer treatment.

Main Methods:

  • Literature review of TG2's role in cancer.
  • Analysis of TG2's interactions with fibronectin and beta-integrins.
  • Examination of TG2's regulation of epithelial-to-mesenchymal transition and stemness.

Main Results:

  • TG2 binds fibronectin and beta-integrins, mediating cell adhesion and matrix interactions.
  • TG2 regulates epithelial-to-mesenchymal transition and stemness, contributing to cancer progression.
  • TG2 translates extracellular signals into activation of oncogenic pathways.

Conclusions:

  • TG2 plays a critical role in cancer development and progression.
  • Targeting TG2 may offer novel therapeutic strategies for cancer treatment.
  • Further research into TG2 mechanisms can improve cancer therapy.